Inappropriate claims from non-equivalent medications in osteoarthritis: a position paper endorsed by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO)
[en] Osteoarthritis (OA) is a progressive joint disease, that occurs frequently in the aging population and is a major cause of disability worldwide. Both glucosamine and chondroitin are biologically active molecules that are substrates for proteoglycan, an essential component of the cartilage matrix. Evidence supports the use of glucosamine and chondroitin as symptomatic slow-acting drugs for osteoarthritis (SYSADOAs) with impact on OA symptoms and disease-modifying effects in the long term. Glucosamine and chondroitin are administered in exogenous form as a sulfate salt and multiple formulations of these agents are available, both as prescription-grade products and nutritional supplements. However, while all preparations may claim to deliver a therapeutic level of glucosamine or chondroitin not all are supported by clinical evidence. Only patented crystalline glucosamine sulfate (pCGS) is shown to deliver consistently high glucosamine bioavailability and plasma concentration in humans, which corresponds to demonstrated clinical efficacy. Similarly, clinical evidence supports only the pharmaceutical-grade chondroitin sulfate. The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) advocates, through careful consideration of the evidence base, that judicious choice of glucosamine and chondroitin formulation is essential to maximize clinical benefit, patient adherence and satisfaction with treatment. In future, the ESCEO recommends that complex molecules with biological activity such as pCGS may be treated as “biosimilars” akin to the European Medicines Agency guidance on biological medicinal products. It seems likely that for all other complex molecules classed as SYSADOAs, the recommendation to use only formulations clearly supported by the evidence-base should apply.
Disciplines :
Public health, health care sciences & services Geriatrics
Author, co-author :
Bruyère, Olivier ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Cooper, Cyrus ; Université de Liège - ULiège > Département des sciences de la santé publique > Département des sciences de la santé publique
Al-Daghri, Nasser ; Université de Liège - ULiège > Département des sciences de la santé publique > Département des sciences de la santé publique
Dennison, Elaine M.
Rizzoli, René ; Université de Liège - ULiège > Département des sciences de la santé publique > Département des sciences de la santé publique
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Language :
English
Title :
Inappropriate claims from non-equivalent medications in osteoarthritis: a position paper endorsed by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO)
Vos T, Flaxman AD, Naghavi M et al (2012) Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2163–2196. https://doi.org/10.1016/s0140-6736(12)61729-2
Cross M, Smith E, Hoy D et al (2014) The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis 73:1323–1330. https://doi.org/10.1136/annrheumdis-2013-204763
Bijlsma JW, Berenbaum F, Lafeber FP (2011) Osteoarthritis: an update with relevance for clinical practice. Lancet 377:2115–2126. https://doi.org/10.1016/S0140-6736(11)60243-2
Nur H, Sertkaya BS, Tuncer T (2017) Determinants of physical functioning in women with knee osteoarthritis. Aging Clin Exp Res. https://doi.org/10.1007/s40520-017-0784-x
Neuprez A, Neuprez AH, Kurth W et al (2017) Profile of osteoarthritic patients undergoing hip or knee arthroplasty, a step toward a definition of the “need for surgery”. Aging Clin Exp Res. https://doi.org/10.1007/s40520-017-0780-1
Bruyere O, Cooper C, Pelletier JP et al (2014) An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum 44:253–263. https://doi.org/10.1016/j.semarthrit.2014.05.014
McAlindon TE, Bannuru RR, Sullivan MC et al (2014) OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthr Cartil 22:363–388. https://doi.org/10.1016/j.joca.2014.01.003
Hochberg MC, Altman RD, April KT et al (2012) American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res 64:465–474. https://doi.org/10.1002/acr.21596
Jordan KM, Arden NK, Doherty M et al (2003) EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 62:1145–1155. https://doi.org/10.1136/ard.2003.011742
Reginster JY, Cooper C, Hochberg M et al (2015) Comments on the discordant recommendations for the use of symptomatic slow-acting drugs in knee osteoarthritis. Curr Med Res Opin 31:1041–1045. https://doi.org/10.1185/03007995.2015.1027183
Martel-Pelletier J, Farran A, Montell E et al (2015) Discrepancies in composition and biological effects of different formulations of chondroitin sulfate. Molecules 20:4277–4289. https://doi.org/10.3390/molecules20034277
EMA (2007) European Medicines Agency, Coordination Group for Mutual Recognition and Decentralised Procedures—Human. Overview of biological active molecules of non-recombinant origin, June 2007. http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/procedural_guidance/Compilation_Biological_Active_Substance_non-recombinant_origin.pdf. Accessed 25 Sept 2017
Setnikar I, Rovati LC (2001) Absorption, distribution, metabolism and excretion of glucosamine sulfate. A review. Arzneimittelforschung 51:699–725. https://doi.org/10.1055/s-0031-1300105
EMA (2014) Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. EMEA/CHMP/BMWP/42832/05 Rev.1. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC500180219.pdf. Accessed 07 Aug 2017
Senin P, Makovec F, Rovati L (1987) Stable compounds of glucosamine sulfate. USA Patent 4642340
Persiani S, Roda E, Rovati LC et al (2005) Glucosamine oral bioavailability and plasma pharmacokinetics after increasing doses of crystalline glucosamine sulfate in man. Osteoarthr Cartil 13:1041–1049. https://doi.org/10.1016/j.joca.2005.07.009
Persiani S, Rotini R, Trisolino G et al (2007) Synovial and plasma glucosamine concentrations in osteoarthritic patients following oral crystalline glucosamine sulphate at therapeutic dose. Osteoarthr Cartil 15:764–772. https://doi.org/10.1016/j.joca.2007.01.019
Jackson CG, Plaas AH, Sandy JD et al (2010) The human pharmacokinetics of oral ingestion of glucosamine and chondroitin sulfate taken separately or in combination. Osteoarthr Cartil 18:297–302. https://doi.org/10.1016/j.joca.2009.10.013
Hamerman D (1989) The biology of osteoarthritis. N Engl J Med 320:1322–1330. https://doi.org/10.1056/NEJM198905183202006
Rovati LC, Girolami F, Persiani S (2012) Crystalline glucosamine sulfate in the management of knee osteoarthritis: efficacy, safety, and pharmacokinetic properties. Ther Adv Musculoskelet Dis 4:167–180. https://doi.org/10.1177/1759720X12437753
Chiusaroli R, Piepoli T, Zanelli T et al (2011) Experimental pharmacology of glucosamine sulfate. Int J Rheumatol 2011:939265. https://doi.org/10.1155/2011/939265
Vlad SC, LaValley MP, McAlindon TE et al (2007) Glucosamine for pain in osteoarthritis: why do trial results differ? Arthritis Rheum 56:2267–2277. https://doi.org/10.1002/art.22728
Reginster JY (2007) The efficacy of glucosamine sulfate in osteoarthritis: financial and nonfinancial conflict of interest. Arthritis Rheum 56:2105–2110. https://doi.org/10.1002/art.22852
Eriksen P, Bartels EM, Altman RD et al (2014) Risk of bias and brand explain the observed inconsistency in trials on glucosamine for symptomatic relief of osteoarthritis: a meta-analysis of placebo-controlled trials. Arthritis Care Res (Hoboken) 66:1844–1855. https://doi.org/10.1002/acr.22376
Towheed TE, Maxwell L, Anastassiades TP et al (2009) Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2:CD002946. https://doi.org/10.1002/14651858.CD002946.pub2
Herrero-Beaumont G, Ivorra JA, Del Carmen Trabado M et al (2007) Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator. Arthritis Rheum 56:555–567. https://doi.org/10.1002/art.22371
Reginster JY, Deroisy R, Rovati LC et al (2001) Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 357:251–256. https://doi.org/10.1016/S0140-6736(00)03610-2
Pavelka K, Gatterova J, Olejarova M et al (2002) Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 162:2113–2123
Jadad AR, Moore RA, Carroll D et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1–12
Runhaar J, Rozendaal RM, Middelkoop MV et al (2017) Subgroup analyses of the effectiveness of oral glucosamine for knee and hip osteoarthritis: a systematic review and individual patient data meta-analysis from the OA trail bank. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2017-211149
Reginster JL, Bruyere O, Cooper C (2017) Different glucosamine sulfate products generate different outcomes on osteoarthritis symptoms. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2017-212251
Zhang W, Nuki G, Moskowitz RW et al (2010) OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthr Cartil 18:476–499. https://doi.org/10.1016/j.joca.2010.01.013
Bjordal JM, Klovning A, Ljunggren AE (2007) Short-term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: a meta-analysis of randomised placebo-controlled trials. Eur J Pain 11:125–138. https://doi.org/10.1016/j.ejpain.2006.02.013
Bhala N, Emberson J, Merhi A et al (2013) Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 382:769–779. https://doi.org/10.1016/s0140-6736(13)60900-9
Castellsague J, Riera-Guardia N, Calingaert B et al (2012) Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf 35:1127–1146. https://doi.org/10.2165/11633470-000000000-00000
Lauder RM (2009) Chondroitin sulphate: a complex molecule with potential impacts on a wide range of biological systems. Complement Ther Med 17:56–62. https://doi.org/10.1016/j.ctim.2008.08.004
Volpi N (2007) Analytical aspects of pharmaceutical grade chondroitin sulfates. J Pharm Sci 96:3168–3180. https://doi.org/10.1002/jps.20997
Volpi N (2009) Quality of different chondroitin sulfate preparations in relation to their therapeutic activity. J Pharm Pharmacol 61:1271–1280. https://doi.org/10.1211/jpp/61.10.0002
McAlindon TE, LaValley MP, Gulin JP et al (2000) Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 283:1469–1475
Richy F, Bruyere O, Ethgen O et al (2003) Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med 163:1514–1522. https://doi.org/10.1001/archinte.163.13.1514
Schneider H, Maheu E, Cucherat M (2012) Symptom-modifying effect of chondroitin sulfate in knee osteoarthritis: a meta-analysis of randomized placebo-controlled trials performed with structum((R)). Open Rheumatol J 6:183–189. https://doi.org/10.2174/1874312901206010183
Reichenbach S, Sterchi R, Scherer M et al (2007) Meta-analysis: chondroitin for osteoarthritis of the knee or hip. Ann Intern Med 146:580–590
Wandel S, Juni P, Tendal B et al (2010) Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ 341:c4675. https://doi.org/10.1136/bmj.c4675
Rainsford KD (2009) Importance of pharmaceutical composition and evidence from clinical trials and pharmacological studies in determining effectiveness of chondroitin sulphate and other glycosaminoglycans: a critique. J Pharm Pharmacol 61:1263–1270. https://doi.org/10.1211/jpp/61.10.0001
Fransen M, Agaliotis M, Nairn L et al (2015) Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens. Ann Rheum Dis 74:851–858. https://doi.org/10.1136/annrheumdis-2013-203954
Zegels B, Crozes P, Uebelhart D et al (2013) Equivalence of a single dose (1200 mg) compared to a three-time a day dose (400 mg) of chondroitin 4&6 sulfate in patients with knee osteoarthritis. Results of a randomized double blind placebo controlled study. Osteoarthr Cartil 21(1):22–27. https://doi.org/10.1016/j.joca.2012.09.017
Kahan A, Uebelhart D, De Vathaire F et al (2009) Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 60:524–533. https://doi.org/10.1002/art.24255
Singh JA, Noorbaloochi S, MacDonald R et al (2015) Chondroitin for osteoarthritis. Cochrane Database Syst Rev 1:CD005614. https://doi.org/10.1002/14651858.CD005614.pub2
Reginster JY, Dudler J, Blicharski T et al (2017) Pharmaceutical-grade Chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteoarthritis: the ChONdroitin versus CElecoxib versus Placebo Trial (CONCEPT). Ann Rheum Dis 76:1537–1543. https://doi.org/10.1136/annrheumdis-2016-210860
AHRQ (2017) Agency for healthcare research and quality, treatment of osteoarthritis of the knee: an update review, May 2017. Comparative Effectiveness Review Number 190. AHRQ Publication No. 17-EHC011-EF
EMA (2010) Guideline on clinical investigation of medicinal products used in the treatment of osteoarthritis. CPMP/EWP/784/97 Rev.1. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003440.pdf. Accessed 07 Aug 2017
Reginster JY, Reiter-Niesert S, Bruyere O et al (2015) Recommendations for an update of the 2010 European regulatory guideline on clinical investigation of medicinal products used in the treatment of osteoarthritis and reflections about related clinically relevant outcomes: expert consensus statement. Osteoarthr Cartil 23:2086–2093. https://doi.org/10.1016/j.joca.2015.07.001
Christiansen BA, Bhatti S, Goudarzi R et al (2015) Management of osteoarthritis with avocado/soybean unsaponifiables. Cartilage 6:30–44. https://doi.org/10.1177/1947603514554992
Blotman F, Maheu E, Wulwik A et al (1997) Efficacy and safety of avocado/soybean unsaponifiables in the treatment of symptomatic osteoarthritis of the knee and hip. A prospective, multicenter, three-month, randomized, double-blind, placebo-controlled trial. Rev Rhum Engl Ed 64:825–834
Maheu E, Mazieres B, Valat JP et al (1998) Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip: a prospective, randomized, double-blind, placebo-controlled, multicenter clinical trial with a six-month treatment period and a two-month followup demonstrating a persistent effect. Arthritis Rheum 41:81–91. https://doi.org/10.1002/1529-0131(199801)41:1<81::AID-ART11>3.0.CO;2-9
Appelboom T, Schuermans J, Verbruggen G et al (2001) Symptoms modifying effect of avocado/soybean unsaponifiables (ASU) in knee osteoarthritis. A double blind, prospective, placebo-controlled study. Scand J Rheumatol 30:242–247
Lequesne M, Maheu E, Cadet C et al (2002) Structural effect of avocado/soybean unsaponifiables on joint space loss in osteoarthritis of the hip. Arthritis Rheum 47:50–58
Maheu E, Cadet C, Marty M et al (2014) Randomised, controlled trial of avocado-soybean unsaponifiable (Piascledine) effect on structure modification in hip osteoarthritis: the ERADIAS study. Ann Rheum Dis 73:376–384. https://doi.org/10.1136/annrheumdis-2012-202485